Hikma & Azanta enter exclusive license agreement for Nimoral in the MENA region
Amman, Jordan & Hellerup, Denmark, February 26, 2015.
Hikma Pharmaceuticals PLC and Azanta A/S, today announced that they had entered an exclusive license agreement for Nimoral in the MENA region.
Hikma is a fast growing specialty pharmaceutical company listed on the London stock exchange that develops, manufactures and markets a broad range of generics, branded generics and in-licensed pharmaceutical products. Hikma has operations in the United States and Europe and has a unique focus in the Middle East and North Africa (“MENA”) with headquarters in Amman, Jordan. From total worldwide revenues of $1,365 million in 2013, approximately 47% was derived from the MENA region.
Azanta is a growing pharma and biotech company with offices in the Nordic countries. Azanta has focus on the development of oncology and women’s healthcare pharmaceuticals, and commercialization of a range of specialty products.
Dr. Claus Møller, Chief Executive Officer of Azanta, commented: “We are very pleased to enter this significant agreement with Hikma. We believe Hikma will be an excellent partner for us for Nimoral in the MENA region, which has a population of more than 380 million people or 6% of the world population. We will immediately start transferring our technology to Hikma for the purpose of manufacturing, registration, marketing, sale and distribution of Nimoral in the region.”
Mazen Darwazah, Hikma’s Vice Chairman and CEO of MENA and Emerging Markets said, “Hikma is committed to improving the treatment of cancer in the MENA region through the development of our oncology product portfolio. This partnership gives Hikma access to a novel, oral anticancer treatment with excellent potential and reinforces our commitment to growing our portfolio through strong partnerships. We look forward to the Phase 3 results for Nimoral and we are very pleased to be working with Azanta to bring this critically needed therapy to the MENA region.”
Nimoral (Nimorazole) is Azanta’s proprietary cancer product in pivotal Phase III development. Nimoral is a radiosensitizer that enhances the effect of radiotherapy in head and neck cancer patients, and the product is being made available under named patient programs throughout the world.
Hikma Pharmaceuticals is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non branded generic and in-licensed products. Hikma’s operations are conducted through three businesses: “Branded”, “Injectables” and “Generics” based principally in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenue of $1,365 million and profit attributable to shareholders of $212 million.
About Azanta A/S
Azanta A/S is a privately owned specialty pharma company primarily operating within oncology, women´s health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets or makes available a string of specialty pharmaceutical products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Angusta for labour induction. In addition, Azanta A/S has a portfolio of low risk development projects for commercialization within the near future.
For further information, please visit www.azanta.com.
Dr. Claus J. Møller, MD – CEO
Tel: + 45 – 70 25 95 45
Fax: + 45 – 70 25 95 46